AVBP ArriVent BioPharma, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1868279 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-11.7%
TTM EPS YoY13.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-48.4%
ROA-45.5%
ROIC (approx.)-60.6%
Asset turnover—
Leverage & solvency
Liabilities / assets5.7%
Debt / equity0.00x
Current ratio—
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio-4.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | — | — | — |
| R&D expense | $153.35M | $79.00M | $64.88M |
| SG&A expense | $24.18M | $15.30M | $9.71M |
| Operating income | -$177.53M | -$94.31M | -$74.59M |
| Net income | -$166.31M | -$80.49M | -$69.33M |
| EBITDA | -$180.56M | — | — |
| EPS (basic) | -4.32 | -2.56 | -32.38 |
| EPS (diluted) | -4.32 | -2.56 | -32.38 |
| Weighted avg. shares (diluted) | 38.46M | 31.47M | 2.14M |
| Balance sheet | |||
| Cash & equivalents | $45.54M | $74.29M | $150.39M |
| Short-term investments | $267.28M | $144.57M | — |
| Current assets | $332.90M | $226.98M | $159.97M |
| Total assets | $333.17M | $274.94M | $163.10M |
| Current liabilities | $25.95M | $17.27M | $11.62M |
| Total liabilities | $25.95M | $17.29M | $11.80M |
| Shareholders' equity | $307.22M | $257.65M | -$153.19M |
| Shares outstanding | 42.45M | 33.71M | 2.75M |
| Cash flow statement | |||
| Operating cash flow | -$160.59M | -$70.21M | -$55.84M |
| Investing cash flow | -$71.23M | -$192.47M | — |
| Financing cash flow | $203.06M | $186.58M | $42.86M |
| Depreciation & amortization | -$3.03M | — | — |
| Stock-based compensation | $12.52M | $3.21M | $895,000 |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.